<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171960</url>
  </required_header>
  <id_info>
    <org_study_id>CS-2018-0009</org_study_id>
    <nct_id>NCT04171960</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the i-STAT TBI Test</brief_title>
  <official_title>Clinical Evaluation of the i-STAT TBI Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Point of Care</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott Point of Care</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical performance of the i-STAT TBI test for&#xD;
      the proposed intended use; to assist in determining the need for a CT scan in patients&#xD;
      presenting with suspected mild traumatic brain injury who are 18 years of age or older. The&#xD;
      secondary objective of this study is the collection of additional data and specimens from all&#xD;
      study subjects that may support other purposes related to the understanding of TBI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>i-STAT TBI Test (elevated/not elevated) relative to standard of care Computed Tomography (CT) findings</measure>
    <time_frame>Within 12 Hours of Traumatic Brain Injury (TBI)</time_frame>
    <description>Results of the i-STAT TBI Test (elevated/not elevated) relative to CT findings for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical sensitivity, clinical specificity, negative predictive value (NPV) and positive predictive value (PPV) of the i-STAT TBI Test</measure>
    <time_frame>Within 12 hours of Traumatic Brain Injury (TBI)</time_frame>
    <description>Clinical sensitivity, clinical specificity, negative predictive value (NPV), and positive predictive value (PPV) of the i-STAT TBI Test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3T Brain Structural and Functional Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>2-Weeks and 6-Months following Traumatic Brain Injury (TBI)</time_frame>
    <description>Sagittal 3D T1 MP-RAGE/IR-SPGR&#xD;
Sagittal 3D T2 GRE/SWAN/SWI&#xD;
Axial DTI&#xD;
Axial Resting State functional MRI (fMRI)&#xD;
Sagittal 3D T2-FLAIR CUBE/SPACE/VISTA&#xD;
Sagittal 3D T2-TSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Specimens for Analysis of Biomarkers and Genetics</measure>
    <time_frame>12-24 Hours, 2-Weeks, and 6-Months following Traumatic Brain Injury (TBI)</time_frame>
    <description>To support future brain research</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Outcome Assessment (Composite Measure)</measure>
    <time_frame>At baseline following Traumatic Brain Injury (TBI)</time_frame>
    <description>Rivermead Post-Concussive Symptom Questionnaire (RPQ)&#xD;
Brief Symptom Inventory (BSI-18)&#xD;
Standardized Assessment of Concussion (SAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-Up Outcome Assessment (Composite Measure)</measure>
    <time_frame>2-Weeks, 6-Weeks, 3-Months, and 6-Months following Traumatic Brain Injury (TBI)</time_frame>
    <description>Glasgow Outcome Scale Extended Revised (R-GOSE)&#xD;
Functional Status Exam (FSE)&#xD;
Posttraumatic Stress Disorder Checklist (PCL-5)&#xD;
Brief Symptom Inventory (BSI-18)&#xD;
Rivermead Post-Concussive Symptom Questionnaire (RPQ)&#xD;
Trail Making Test (TMT)&#xD;
Wechsler Adult Intelligence Scale IV - Processing Speed Index (WAIS IV-PSI)&#xD;
Rey Auditory Verbal Learning Test (RAVLT)&#xD;
Qualify of Life After Brain Injury -Overall Scale (QOLIBRI-OS)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Acute Blood Biomarker Branch</arm_group_label>
    <description>Blood draw within 12 hours of injury for i-STAT Testing then processing for storage for future use&#xD;
Blood draw between 12 to 24 hours of injury then processing for storage for future use&#xD;
In-Person Outcome Assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Blood Biomarker Plus Follow-up Branch</arm_group_label>
    <description>Blood draw at 2 weeks and 6 months following injury then processing for storage for future use&#xD;
In-Person Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury&#xD;
Phone Outcome Assessment at 3 months following injury&#xD;
3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Draw Within 12 Hours of Injury</intervention_name>
    <description>- Specimens collected for i-STAT testing and, if applicable, for optional collection of DNA for possible future genetic testing.</description>
    <arm_group_label>Acute Blood Biomarker Branch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3T MRI</intervention_name>
    <description>- 3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury.</description>
    <arm_group_label>Acute Blood Biomarker Plus Follow-up Branch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>In-Person Outcome Assessment at Baseline</intervention_name>
    <description>-3 Outcome Assessments administered at Baseline.</description>
    <arm_group_label>Acute Blood Biomarker Branch</arm_group_label>
    <arm_group_label>Acute Blood Biomarker Plus Follow-up Branch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>In-Person Outcome Assessment at Follow-Up</intervention_name>
    <description>- Full set of Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury.</description>
    <arm_group_label>Acute Blood Biomarker Plus Follow-up Branch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phone Outcome Assessment</intervention_name>
    <description>- 6 Outcome Assessments administered at 3 months following injury by Phone.</description>
    <arm_group_label>Acute Blood Biomarker Plus Follow-up Branch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Draw After 12 Hours of Injury</intervention_name>
    <description>- Specimens collected at 12-24 hours, 2 weeks, and 6 month following injury then processed for storage for future use.</description>
    <arm_group_label>Acute Blood Biomarker Branch</arm_group_label>
    <arm_group_label>Acute Blood Biomarker Plus Follow-up Branch</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll patients presenting to the Healthcare Facility with a history of acute TBI&#xD;
        within the last 12 hours (acute injury) in which the patient has sustained a traumatically&#xD;
        induced* physiological disruption of brain function, as manifested by â‰¥ one of the&#xD;
        following:&#xD;
&#xD;
          -  Any period of loss of consciousness&#xD;
&#xD;
          -  Any loss of memory for events immediately before or after the accident&#xD;
&#xD;
          -  Any alteration of mental state at the time of the accident (feeling dazed,&#xD;
             disoriented, and/or confused)&#xD;
&#xD;
          -  Focal neurologic deficits that may or may not be permanent&#xD;
&#xD;
               -  Traumatically induced includes the head being struck, the head striking an&#xD;
                  object, or the brain undergoing an acceleration/deceleration movement without&#xD;
                  direct external trauma to the head&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Acute Blood Biomarker Branch Subject Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older.&#xD;
&#xD;
          2. Subject or Legally Authorized Representative (LAR) provided informed consent for the&#xD;
             Acute Blood Biomarker Branch (waiver of consent may be acceptable, per IRB).&#xD;
&#xD;
          3. Subject presented to a health care facility or emergency department with a suspected&#xD;
             traumatic brain injury resulting from an insult to the head by an external force&#xD;
             within 12 hours of the injury.&#xD;
&#xD;
          4. Subject has a computed tomography (CT) scan of the head with all sequences (bone and&#xD;
             soft tissue) ordered as part of standard of care at the enrolling facility, or are&#xD;
             transferred to the enrolling facility with a head CT scan sent from the originating&#xD;
             facility.&#xD;
&#xD;
          5. As a result of this head injury, the subject has sustained a traumatically induced&#xD;
             physiological disruption of brain function, as manifested by at least one of the&#xD;
             following:&#xD;
&#xD;
               1. Any period of loss of consciousness&#xD;
&#xD;
               2. Any loss of memory for events immediately before or after the injury&#xD;
&#xD;
               3. Any alteration of mental state at the time of the injury&#xD;
&#xD;
               4. Focal neurological deficits that may or may not be transient&#xD;
&#xD;
        Acute Blood Biomarker Branch Subject Exclusion Criteria:&#xD;
&#xD;
          1. Previous enrollment in this study, CS-2018-0009&#xD;
&#xD;
          2. Current (on-going) enrollment in a therapeutic or interventional clinical trial (drug&#xD;
             or device)&#xD;
&#xD;
          3. Primary diagnosis at the enrolling facility of ischemic or hemorrhagic stroke&#xD;
&#xD;
          4. Time of injury is unknown and cannot be estimated&#xD;
&#xD;
          5. Presented with penetrating head trauma or spinal cord injury (American Spinal Injury&#xD;
             Association [ASIA] score of C or worse) at the enrolling facility&#xD;
&#xD;
          6. Standard of care head CT scan procedures not completed prior to Emergency Department&#xD;
             (ED) discharge.&#xD;
&#xD;
          7. Prisoners or patients in custody&#xD;
&#xD;
          8. Patients on psychiatric hold&#xD;
&#xD;
        Follow-up Branch Subject Inclusion Criteria:&#xD;
&#xD;
          1. Enrollment in Acute Blood Biomarker Branch&#xD;
&#xD;
          2. Subject or LAR provided informed consent for the Acute Blood Biomarker Branch and the&#xD;
             Follow-up Branch&#xD;
&#xD;
        Follow up Branch Subject Exclusion Criteria:&#xD;
&#xD;
        1. Conditions or circumstances that would interfere with follow-up and outcome assessment,&#xD;
        as determined by the principal investigator or delegate. Examples include:&#xD;
&#xD;
          1. Significant polytrauma&#xD;
&#xD;
          2. Major debilitating baseline mental health disorders (e.g. schizophrenia or bipolar&#xD;
             disorder)&#xD;
&#xD;
          3. Major debilitating neurological disease (e.g. stroke, cerebrovascular accident,&#xD;
             dementia, tumor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Hospital of Indiana</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>i-STAT</keyword>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

